arrow
F

Francesco Buccisano

University Tor Vergata
H指数:50
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Characterization of FLT3-ITD-mutated leukemic stem cells: functional and clinical insights

FLT3-ITD突变白血病干细胞的表征:功能与临床见解

2026-09-280
OAAI
Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial

非适应证急性髓系白血病患者接受维奈克拉联合去甲基化药物的疗效:GIMEMA AML2320试验结果

2026-09-050
PRE
Use of Peripheral Blood to Measure Residual Disease by Flow Cytometry in Adult Acute Myeloid Leukemia: Final Report of the Prospective GIMEMA AML1310 Trial

使用外周血通过流式细胞术测量成人急性髓系白血病残留病灶:GIMEMA AML1310前瞻性试验的最终报告

2026-09-020
OAAI
APL-like subset within NPM1-mutated AML: A distinct immunophenotype correlating with early vascular complications

NPM1突变AML中APL样亚群:一种与早期血管并发症相关的独特免疫表型

2026-04-160
OA
Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA/ELN expert panel

王, S.A.; Arenillas, L.; Buccisano, F.; Bruggemann, M.; Kern, W.; Menes, M.; Plesa, A.; Stone, L.; Wellnitz, D.; Westerman, D.A.; 等. 报告原始细胞百分比以评估急性白血病反应:EHA/ELN专家小组的建议. Haematologica 2025, 4, 288228. [Google Scholar] [CrossRef]

2026-01-012
OA
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia

流式细胞术基线可测残留病评估中定量下限作为低水平截断值的预后相关性研究

Leukemia
IF13.4
2025-12-100
OA
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee

可测量残留疾病指导下的干预措施在异基因造血细胞移植的急性髓系白血病患者中的应用:欧洲血液与骨髓移植学会实践协调与指南委员会的最佳实践建议

2025-10-270
PRE
Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study

fostamatinib 在 ITP 患者中的真实世界有效性与安全性:意大利多中心经验。GIMEMA ITP1122 研究

2025-08-250
PRE
Validation Study of Analytical Methods for Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia

基于多参数流式细胞术的急性髓系白血病可测量微小残留病评估的分析方法验证研究

2025-05-080
OA
The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia
2024-04-014
OAAI
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel
2023-09-067
PRE
Reliability of flow-cytometry in diagnosis and prognostic stratification of myelodysplastic syndromes: correlations with morphology and mutational profile

流式细胞术在骨髓增生异常综合征诊断和预后分层中的可靠性: 与形态学和突变特征的相关性

2023-08-031
OAAI
MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs' patients
LEUKEMIA
IF13.4
2023-06-228
OA